Yet GSK is clearly healing from its multiple comorbidities — the worst of which was the (now largely resolved) legal overhang related to heartburn medicine Zantac. Chief executive Emma Walmsley also ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Spandana Sphoorty Financial Ltd, Reliance Power Ltd, Fusion Finance Ltd and Aarti Pharmalabs Ltd are among the other gainers in the BSE's 'A' group today, 06 February 2025.

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...

CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product DevelopmentTonix is Preparing for Potential Launch ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

The UK biotech sector raised £3.5 billion in equity financing last year amid challenges, according to a BIA report.